Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12840678 | 0.84 | KMT2A (0.34) | KMT2ATDP1MEN1CDK5CDK5R1 | |
| SCHEMBL19287187 | 0.83 | CYP1A2 (0.38) | KMT2ATDP1MEN1CDK5CDK5R1 | |
| SCHEMBL20192290 | 0.81 | ALDH1A1 (0.34) | KMT2ATDP1MEN1CDK5CDK5R1 | |
| SCHEMBL1398316 | 0.74 | ADAMTS5 (0.42) | KMT2AMEN1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL20705465 | 0.70 | CYP1A2 (0.37) | KMT2ATDP1MEN1CDK5CDK5R1 | |
| SCHEMBL19538511 | 0.69 | CYP1A2 (0.39) | KMT2ATDP1MEN1CDK5CDK5R1 | |
| SCHEMBL16708654 | 0.68 | HCAR3 (0.36) | ALDH1A1CCNA2CDK2HPGDHSD17B10 | |
| SCHEMBL12674552 | 0.66 | CDK5 (0.39) | KMT2ATDP1MEN1CDK5CDK5R1 | |
| SCHEMBL11188433 | 0.64 | HSD17B10 (0.40) | KMT2AMEN1CDK5CDK5R1ALDH1A1 | |
| SCHEMBL27916221 | 0.64 | GABRA5 (0.38) | CDK5CDK5R1ALDH1A1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | KMT2A 4534/4885TDP1 2605/4885MEN1 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.